308 related articles for article (PubMed ID: 31126963)
41. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
42. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia.
Arnold DM; Vrbensky JR; Karim N; Smith JW; Liu Y; Ivetic N; Kelton JG; Nazy I
Br J Haematol; 2017 Jul; 178(2):302-307. PubMed ID: 28444742
[TBL] [Abstract][Full Text] [Related]
43. Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children.
Roganovic J
Eur J Pediatr; 2005 May; 164(5):334. PubMed ID: 15711954
[No Abstract] [Full Text] [Related]
44. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
[TBL] [Abstract][Full Text] [Related]
45. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
46. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
47. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
48. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
[TBL] [Abstract][Full Text] [Related]
49. B-cell depletion in immune thrombocytopenia.
Psaila B; Cooper N
Lancet; 2015 Apr; 385(9978):1599-601. PubMed ID: 25662418
[No Abstract] [Full Text] [Related]
50. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
D'Arena G; Capalbo S; Laurenti L; Del Poeta G; Nunziata G; Deaglio S; Spinosa G; Tarnani M; De Padua L; Califano C; Ferrara F; Cascavilla N
Eur J Haematol; 2010 Dec; 85(6):502-7. PubMed ID: 20846302
[TBL] [Abstract][Full Text] [Related]
51. [Rituximab for treatment of patients with systemic autoimmune diseases].
García Hernández FJ; Ocaña Medina C; González León R; Garrido Rasco R; Colorado Bonilla R; Castillo Palma MJ; Sánchez Román J
Med Clin (Barc); 2007 Mar; 128(12):458-62. PubMed ID: 17408540
[TBL] [Abstract][Full Text] [Related]
52. [Good response to treatment with rituximab in a child with refractory idiopathic thrombocytopenic purpura].
Fríguls-Francitorra B; Almazán-Castro F; Manchón GJ
Med Clin (Barc); 2006 Sep; 127(12):478-9. PubMed ID: 17040639
[No Abstract] [Full Text] [Related]
53. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.
Chugh S; Darvish-Kazem S; Lim W; Crowther MA; Ghanima W; Wang G; Heddle NM; Kelton JG; Arnold DM
Lancet Haematol; 2015 Feb; 2(2):e75-81. PubMed ID: 26687612
[TBL] [Abstract][Full Text] [Related]
54. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
55. Management of Chronic Immune Thrombocytopenia and Presumed Autoimmune Hepatitis in a Child with IKAROS Haploinsufficiency.
Groth DJ; Lakkaraja MM; Ferreira JO; Feuille EJ; Bassetti JA; Kaicker SM
J Clin Immunol; 2020 May; 40(4):653-657. PubMed ID: 32319000
[No Abstract] [Full Text] [Related]
56. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
[TBL] [Abstract][Full Text] [Related]
57. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
[No Abstract] [Full Text] [Related]
58. Update on the management of immune thrombocytopenic purpura in children.
Tarantino MD; Bolton-Maggs PH
Curr Opin Hematol; 2007 Sep; 14(5):526-34. PubMed ID: 17934363
[TBL] [Abstract][Full Text] [Related]
59. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
60. [Recurrent infections in an ITP patient treated with rituximab].
Rosenberg-Bezalel S; Asher I; Sthoeger Z
Harefuah; 2012 Nov; 151(11):617-9, 655. PubMed ID: 23367730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
